Research Brief

An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Jamie S. Myers

Alana Manson

Sandra A. Billinger

William Parker

Jill Hamilton-Reeves

Francisco J. Diaz

Ron Krebill

Sally Maliski

prostate cancer, cognitive function, androgen deprivation, central adiposity
ONF 2022, 49(2), 142-150. DOI: 10.1188/22.ONF.142-150

Objectives: To prospectively assess cognitive function, anthropomorphic measures, and bone mineral density in men receiving androgen deprivation therapy (ADT) for prostate cancer; explore relationships between cognitive function and central adiposity; and gather preliminary data from a personalized education, exercise, and nutrition intervention.

Sample & Setting: 33 participants consented from a randomized controlled intervention trial.

Methods & Variables: Neurocognitive performance and self-report of cognitive function were assessed at baseline and 6 and 12 months. Dual-energy x-ray absorptiometry (DEXA) scans were obtained at baseline and 6 months.

Results: No between-group differences in cognitive function were demonstrated. Increased visceral adiposity was not associated with decrements in visuospatial abilities. Significant increases in fat mass without increases in body mass index or waist–hip ratio provided further evidence for DEXA as the preferred central adiposity measure.

Implications for Nursing: Well-powered prospective research is needed to fully characterize the effects of ADT on cognitive function and the potential benefits of exercise and nutrition-based interventions.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.